Browse by Aston Author

2015

Wilding, J.P.H.; Bailey, C.J.; Rigney, U.; Blak, B.; Beekman, W. and Emmas, C.E. (2015). Changes in HbA1c and weight in type 2 diabetes patients initiating dapagliflozin treatment in routine UK primary care. Diabetologia, 58 (Suppl.), S352-S356.

Bailey, C.J. (2015). Safety of antidiabetes medications:an update. Clinical pharmacology and therapeutics, 98 (2), 185–195.

Bailey, C.J. (2015). The current drug treatment landscape for diabetes and perspectives for the future. Clinical pharmacology and therapeutics, 98 (2), 170–184.

2013

Bailey, C.J.; Berria, R.; Stager, W.; Gautier, J.-F.; Aronson, R. and Ahrén, B. (2013). Consistent reduction of postprandial glucagon and insulin by lixisenatide in the GetGoal clinical trial programme. Diabetologia, 56 (Suppl.), S403.

2012

Bailey, C.J.; Iqbal, N.; T'joen, C. and List, J.F. (2012). Dapagliflozin monotherapy in drug-naïve patients with diabetes:a randomized-controlled trial of low-dose range. Diabetes, Obesity and Metabolism, 14 (10), pp. 951-959.

Pararasa, C.; Gao, D.; Dunston, C.R.; Bailey, C.J. and Griffiths, H.R. (2012). Palmitate induces phenotype changes in monocytes via de novo ceramide synthesis. Free Radical Biology and Medicine, 53 (Supple), S136.

2011

Paget, M.B.; Murray, H.E.; Bailey, C.J.; Flatt, P.R. and Downing, R. (2011). Rotational co-culture of clonal β-cells with endothelial cells:effect of PPAR-γ agonism in vitro on insulin and VEGF secretion. Diabetes, Obesity and Metabolism, 13 (7), pp. 662-668.

Irwin, N.; McKinney, J.M.; Bailey, C.J.; McClenaghan, N.H. and Flatt, P.R. (2011). Acute and long-term effects of peroxisome proliferator-activated receptor-γ activation on the function and insulin secretory responsiveness of clonal beta-cells. Hormone and Metabolic Research, 43 (4), pp. 244-249.

Bailey, C.J. and Kodack, M. (2011). Patient adherence to medication requirements for therapy of type 2 diabetes. International Journal of Clinical Practice, 65 (3), pp. 314-322.

2007

Alberti, K.G.M.M.; Bailey, C.J.; Blonde, L.; Felton, A.M.; Zimmet, P. and , and on behalf of the Global Partnership for Effective Diabetes M (2007). Partnering with governments and other institutions:driving change in diabetes care. International Journal of Clinical Practice, 61 (Suppl.), pp. 38-46.

2006

Richardson, D.K.; Jones, R.B. and Bailey, C.J. (2006). The primary amine metabolite of sibutramine stimulates lipolysis in adipocytes isolated from lean and obese mice and in isolated human adipocytes. Hormone and Metabolic Research, 38 (11), pp. 727-731.

Bailey, C.J. (2006). Fenofibrate and cardiovascular risk:a synopsis and commentary on (FIELD). Diabetic Medicine, 23 (2), pp. 109-112.

2003

Green, B.D.; Gault, V.A.; Mooney, M.H.; Irwin, N.; Bailey, C.J.; Harriott, P.; Greer, B.; Flatt, P.R. and O'Harte, F.P.M. (2003). Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. Journal of Molecular Endocrinology, 31 (3), pp. 529-540.